## Highlights of This Issue

### SPECIAL FEATURES

**CCR Translations**

- **5217** Overcoming Antiangiogenic Resistance
  James C. Yao and Alexandria Phan
  *See article p. 5299*

**CCR Perspectives in Drug Approval**

- **5220** The European Medicines Agency: An Overview of Its Mission, Responsibilities, and Recent Initiatives in Cancer Drug Regulation
  Francesco Pignatti, Iordanis Gravanis, Ralf Herold, Spiros Vamvakas, Bertil Jonsson, and Michel Marty

**Molecular Pathways**

- **5226** Angiopoietin-2 TIEs Up Macrophages in Tumor Angiogenesis
  Michele De Palma and Luigi Naldini

- **5233** Prostate Cancer Immunotherapy
  Kenneth F. May, Jr., James L. Gulley, Charles G. Drake, Glenn Dranoff, and Philip W. Kantoff

**Special Report**

- **5239** SWOG Cooperative Group Biorepository Resource: Access for Scientific Research Studies
  Carolyn J. Hoban, Wilbur A. Franklin, Kenneth J. Kopecky, and Laurence H. Baker

**Review**

- **5247** Prognostic Immune Markers in Non–Small Cell Lung Cancer
  Kei Suzuki, Stefan S. Kachala, Kyuichi Kadota, Ronglai Shen, Qianxing Mo, David G. Beer, Valerie W. Rusch, William D. Travis, and Prasad S. Adusumilli

## HUMAN CANCER BIOLOGY

**Novel Functional Germline Variants in the VEGF Receptor 2 Gene and Their Effect on Gene Expression and Microvessel Density in Lung Cancer**


**Clonal Relationship of Classical Hodgkin Lymphoma and its Recurrences**

- Ellen C. Obermann, Nadine Mueller, Alexander Rufle, Thomas Menter, Esther Mueller-Garamvoelgyi, Gieri Cathomas, Stephan Dirnhoffer, and Alexandar Tzankov

**FGFR Signaling Promotes the Growth of Triple-Negative and Basal-Like Breast Cancer Cell Lines Both In Vitro and In Vivo**

- Rachel Sharpe, Alex Pearson, Maria T. Herrera-Abreu, Damian Johnson, Alan Mackay, Jonathan C. Welti, Rachael Natrajani, Andrew R. Reynolds, Jorge S. Reis-Filho, Alan Ashworth, and Nicholas C. Turner

**Regulatory Role of mir-203 in Prostate Cancer Progression and Metastasis**

- Sharanjot Saini, Shahana Majid, Soichiro Yamamura, Laura Tabatabai, Seong O. Suh, Varahram Shahrnoy, Yi Chen, Guoren Deng, Yuichiro Tanaka, and Rajvir Dahiya

## CANCER THERAPY: PRECLINICAL

**Brivanib, a Dual FGF/VEGF Inhibitor, Is Active Both First and Second Line against Mouse Pancreatic Neuroendocrine Tumors Developing Adaptive/Evasive Resistance to VEGF Inhibition**

- Elizabeth Allen, Ian B. Walters, and Douglas Hanahan
  *See commentary p. 5217*
In Vitro and In Vivo Selective Antitumor Activity of a Novel Orally Bioavailable Proteasome Inhibitor MLN9708 against Multiple Myeloma Cells

Dhminder Chauhan, Ze Tian, Bin Zhou, Deborah Kuhn, Robert Orłowski, Noopur Raje, Paul Richardson, and Kenneth C. Anderson

Gastric Cancer Growth Control by BEZ235 In Vivo Does Not Correlate with PI3K/mTOR Target Inhibition but with [18F]FLT Uptake

Thorsten Fuereder, Thomas Wanek, Pamina Pflegerl, Agnes Jaeger-Lansky, Doris Hoeflmayer, Sabine Strommer, Claudia Kuntner, Friedrich Wrba, Johannes Werzowa, Michael Heyna, Markus Müller, Oliver Langer, and Volker Wacheck

Regression of Glioma in Rat Models by Intranasal Application of Parvovirus H-1

Irina Kiprianova, Nadja Thomas, Ali Ayache, Manuel Fischer, Barbara Leuchs, Michèle Klein, Jean Römmlaere, and Jörg R. Schlehofer

Determinants of Successful CD8+ T-Cell Adoptive Immunotherapy for Large Established Tumors in Mice

Christopher A. Klebanoff, Luca Gattinoni, Douglas C. Palmer, Pawel Muranski, Yun Ji, Christian S. Hinrichs, Zachary A. Borman, Sid P. Kerkar, Christopher D. Scott, Steven E. Finkelstein, Steven A. Rosenberg, and Nicholas P. Restifo

PM02734 (Elisidepsin) Induces Caspase-Independent Cell Death Associated with Features of Autophagy, Inhibition of the Akt/mTOR Signaling Pathway, and Activation of Death-Associated Protein Kinase

Yi-He Ling, Miguel Aracil, Yiyu Zou, Ziqiang Yuan, Bo Lu, José Jimeno, Ana Maria Cuervo, and Roman Perez-Soler

Targeting Src in Mucinous Ovarian Carcinoma


Lupeol, a Novel Androgen Receptor Inhibitor: Implications in Prostate Cancer Therapy

Hifzur Rahman Siddique, Shrawan Kumar Mishra, R. Jeffery Karnes, and Mohammad Saleem

Induction of HLA-DPβ1–Restricted Anti-Survivin Th1 and Th2 Responses Using an Artificial Antigen-Presenting Cell

Makito Tanaka, Marcus O. Butler, Sascha Ansén, Osamu Imataki, Alla Berezovskaya, Lee M. Nadler, and Naoto Hirano

Resveratrol Selectively Induces DNA Damage, Independent of Smad4 Expression, in Its Efficacy against Human Head and Neck Squamous Cell Carcinoma

Alpna Tyagi, Mallikarjununa, Takahata, Barbara Frederic, Chapla Agarwal, Sunitha Sriratvala, Rajesh Agarwal, and Robert A. Scelfani

Role of Smac in Determining the Chemotherapeutic Response of Esophageal Squamous Cell Carcinoma

Yang Xu, Lanping Zhou, Jing Huang, Fang Liu, Jian Yu, Qimin Zhan, Lin Zhang, and Xiaohang Zhao

Antitumor Activity of YM155, a Selective Small-Molecule Survivin Suppressor, Alone and in Combination with Docetaxel in Human Malignant Melanoma Models

Kentaro Yamanaka, Takahito Nakahara, Tomohiro Yamauchi, Aya Kita, Masahiro Takeuchi, Fumiko Kyionaga, Naoki Kaneko, and Masao Sasamata

Effective Targeting of Triple-Negative Breast Cancer Cells by PF-492847, a Novel Oral Inhibitor of Hsp 90

Pramod P. Mehta, Pamela Whalen, Sangita M. Baxi, Pei-Pei Kung, Shinji Yamazaki, and Min-Jean Yin

Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group


IMAGING, DIAGNOSIS, PROGNOSIS

Prognostic Model for Survival in Patients with Metastatic Renal Cell Carcinoma: Results from the International Kidney Cancer Working Group

BARD1 Expression Predicts Outcome in Colon Cancer
Judith C. Sporn, Torsten Hothorn, and Barbara Jung

Gene Expression Profiling of Fixed Tissues Identified Hypoxia-Inducible Factor-1α, VEGF, and Matrix Metalloproteinase-2 as Biomarkers of Lymph Node Metastasis in Hepatocellular Carcinoma
Zuo-Lin Xiang, Zhao-Chong Zeng, Jia Fan, Zhao-You Tang, Hai-Ying Zeng, and Dong-Mei Gao

CANCER THERAPY: CLINICAL

Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and Temozolomide
Stuart A. Grossman, Xiaobu Ye, Glenn Lesser, Andrew Sloan, Hetty Carraway, Serena Desideri, and Steven Plantaditis for the NABTT CNS Consortium

A Phase II Study of Pazopanib in Asian Patients with Recurrent/Metastatic Nasopharyngeal Carcinoma
Wan-Teck Lim, Quan-Sing Ng, Percy Ivy, Swan-Swan Leong, Onkar Singh, Balram Chowbay, Fei Gao, Choon Huat Thng, Boon-Cher Goh, Daniel Shao-Weng Tan, Tong San Koh, Chee-Keong Toh, and Eng-Huat Tan

PREDICTIVE BIOMARKERS AND PERSONALIZED MEDICINE

Platinum Sensitivity–Related Germline Polymorphism Discovered via a Cell-Based Approach and Analysis of Its Association with Outcome in Ovarian Cancer Patients

Membranous Expression of Ectodomain Isoforms of the Epidermal Growth Factor Receptor Predicts Outcome after Chemoradiotherapy of Lymph Node–Negative Cervical Cancer
Cathinka Halle, Malin Lando, Debbie Hege Sølvengsrud, Trevor Clancy, Marit Holden, Kolbein Sundal, Gunnar B. Kristensen, Ruth Holm, and Heidi Lyng

XPF Expression Correlates with Clinical Outcome in Squamous Cell Carcinoma of the Head and Neck

CORRECTIONS

Correction: Regulation of HMGAI Expression by MicroRNA-296 Affects Prostate Cancer Growth and Invasion

Correction: Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate
ABOUT THE COVER

Immunohistochemical analysis confirmed that YM155 reduced survivin protein levels, whereas docetaxel treatment increased p34 Thr-survivin protein at G2/M mitotic arrest. Furthermore, the concomitant treatment YM155 apparently decreased the docetaxel-induced survivin upregulation below the basal level in SK-MEL-5 human malignant melanoma cell. For further details, please see Yamanaka and colleagues on page 5423 in this issue.
Clinical Cancer Research

17 (16)

Clin Cancer Res 2011;17:5215-5524.

Updated version  Access the most recent version of this article at:  
http://clincancerres.aacrjournals.org/content/17/16

E-mail alerts  Sign up to receive free email-alerts related to this article or journal.  
Reprints and Subscriptions  To order reprints of this article or to subscribe to the journal, contact the AACR Publications Department at pubs@aacr.org.  
Permissions  To request permission to re-use all or part of this article, contact the AACR Publications Department at permissions@aacr.org.